Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Farmers Insurance
Boehringer Ingelheim
Express Scripts
Mallinckrodt
QuintilesIMS
Johnson and Johnson
Chinese Patent Office

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020347

« Back to Dashboard

NDA 020347 describes HYTRIN, which is a drug marketed by Abbott and is included in two NDAs. Additional details are available on the HYTRIN profile page.

The generic ingredient in HYTRIN is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the terazosin hydrochloride profile page.
Summary for 020347
Tradename:HYTRIN
Applicant:Abbott
Ingredient:terazosin hydrochloride
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 14, 1994TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 14, 1994TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 14, 1994TE:RLD:Yes

Expired US Patents for NDA 020347

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-003 Dec 14, 1994 ➤ Sign Up ➤ Sign Up
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-001 Dec 14, 1994 ➤ Sign Up ➤ Sign Up
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-001 Dec 14, 1994 ➤ Sign Up ➤ Sign Up
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-002 Dec 14, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Deloitte
Fuji
Julphar
Covington
Cerilliant
Harvard Business School
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.